The Clorox Company (NYSE:CLX) Stock Holdings Raised by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. has increased its stake in The Clorox Company (NYSE:CLX) by 0.7%, now owning 752,986 shares valued at approximately $110.9 million.
• Clorox recently announced a quarterly dividend of $1.24, marking an increase from the previous $1.22, which offers a dividend yield of 4.1%.
• Analysts have adjusted their price targets for Clorox, with UBS Group reducing its target from $150 to $134 and others following suit, reflecting a cautious outlook on the stock.

Charles Schwab Investment Management Inc. lifted its holdings in shares of The Clorox Company (NYSE:CLX - Free Report) by 0.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 752,986 shares of the company's stock after buying an additional 4,866 shares during the period. Charles Schwab Investment Management Inc. owned 0.61% of Clorox worth $110,877,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of CLX. Wellington Management Group LLP grew its position in shares of Clorox by 18.8% during the 4th quarter. Wellington Management Group LLP now owns 4,074 shares of the company's stock valued at $662,000 after buying an additional 646 shares during the last quarter. FIL Ltd grew its position in shares of Clorox by 78.0% during the 4th quarter. FIL Ltd now owns 3,159 shares of the company's stock valued at $513,000 after buying an additional 1,384 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Clorox during the 4th quarter valued at about $37,935,000. Rockefeller Capital Management L.P. grew its position in shares of Clorox by 5.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 16,003 shares of the company's stock valued at $2,599,000 after buying an additional 847 shares during the last quarter. Finally, Savvy Advisors Inc. bought a new stake in shares of Clorox during the 4th quarter valued at about $946,000. Institutional investors own 78.53% of the company's stock.

Clorox Trading Down 2.2%

Shares of NYSE:CLX opened at $122.15 on Tuesday. The company has a 50 day moving average of $125.35 and a 200-day moving average of $137.38. The firm has a market cap of $15.05 billion, a P/E ratio of 18.73, a P/E/G ratio of 1.00 and a beta of 0.49. The Clorox Company has a twelve month low of $117.35 and a twelve month high of $171.37. The company has a current ratio of 0.84, a quick ratio of 0.57 and a debt-to-equity ratio of 5.15.

Clorox (NYSE:CLX - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, topping analysts' consensus estimates of $2.24 by $0.63. The company had revenue of $1.99 billion during the quarter, compared to analyst estimates of $1.94 billion. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The business's revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.82 EPS. As a group, analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Clorox Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 29th. Investors of record on Wednesday, August 13th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date is Wednesday, August 13th. This is an increase from Clorox's previous quarterly dividend of $1.22. Clorox's payout ratio is presently 74.85%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CLX. UBS Group lowered their price objective on shares of Clorox from $150.00 to $134.00 and set a "neutral" rating for the company in a research report on Thursday, July 17th. JPMorgan Chase & Co. reduced their target price on shares of Clorox from $144.00 to $140.00 and set a "neutral" rating for the company in a research note on Friday, July 25th. Barclays reduced their target price on shares of Clorox from $129.00 to $119.00 and set an "underweight" rating for the company in a research note on Tuesday, July 15th. Morgan Stanley reduced their target price on shares of Clorox from $150.00 to $137.00 and set an "equal weight" rating for the company in a research note on Friday, August 1st. Finally, Citigroup reissued a "neutral" rating and set a $135.00 target price (down from $140.00) on shares of Clorox in a research note on Tuesday, July 15th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $143.36.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.